Objective:　To　prepare　the　TAT-ASPP2　fusion　protein　and　investigate　its　inhibitory　effect　against　the　proliferation　of　glioma　U-87MG　and　U251　cells.　Methods:　TAT-ASPP2　specific　primer　was　designed　and　recombinant　prokaryotic　expression　vector　pET-TAT-ASPP2　was　constructed　using　the　In-Fusion　cloning　technique.　After　identified　by　double　endonuclease　digestion　and　DNA　sequencing,　pET-TAT-ASPP2　vector　was　transformed　into　E.　coli　BL21　and　TAT-ASPP2　fusion　protein　was　induced　by　IPTG.　TAT-ASPP2　fusion　protein　was　further　identified　by　SDS-PACE　and　Western　blotting　analysis.　The　effects　of　TAT-ASPP2　fusion　protein　on　proliferation　of　U-87MG　and　U251　cells　were　detected　by　MTT　assay.　Results:　The　prokaryotic　expression　plasmid　pET-TAT-ASPP2　was　successfully　constructed,　and　TAT-ASPP2　fusion　protein　was　induced　by　IPTG　in　transformed　E.　coli　BL21;　the　molecular　weight　of　the　fusion　protein　was　about　128　000　and　it　could　be　specifically　recognized　by　ASPP2　antibody.　TAT-ASPP2　fusion　protein　significantly　inhibited　the　proliferation　of　U-87MG　and　U-251　cells,　with　the　inhibitory　rates　being　about　(65.0　±　3.0)%　and　(64.7　±　2.5)%,　respectively;　while　ASPP2　protein　did　not　inhibit　the　proliferation　of　U-87MG　and　U-251　cells.　Conclusion:　TAT-ASPP2　fusion　protein　has　been　successfully　expressed　and　purified,　and　the　fusion　protein　can　significantly　inhibit　the　proliferation　of　glioma　cells.